Johnathon Elliot

Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapy

Jad Othman, Ing Soo Tiong, Jenny O’Nions et al. · Blood · 2023 · 65 citations · Full text

Medicine, Hematology, Oncology +14

Erythropoietin mimics the acute phase response in critical illness

Johnathon Elliot, Tanit Virankabutra, Stephen Jones et al. · Critical Care · 2003 · 55 citations · Full text

Medicine, Hematology, Critical Care Pharmacotherapy +14

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery

Matthew R. Wilson, Toby A. Eyre, Nicolás Martínez‐Calle et al. · Blood Advances · 2020 · 54 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS

Jad Othman, Ho Pui Jeff Lam, Sarah Leong et al. · Blood Neoplasia · 2024 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Missed irradiation of cellular blood components for vulnerable patients: Insights from 10 years of <scp>SHOT</scp> data

Johnathon Elliot, Shruthi Narayan, Debbi Poles et al. · Transfusion · 2020 · 22 citations · Full text

Medicine, Hematology, Radiation Protection +16